UY25711A1 - Administración de agente activo en polvo seco - Google Patents
Administración de agente activo en polvo secoInfo
- Publication number
- UY25711A1 UY25711A1 UY25711A UY25711A UY25711A1 UY 25711 A1 UY25711 A1 UY 25711A1 UY 25711 A UY25711 A UY 25711A UY 25711 A UY25711 A UY 25711A UY 25711 A1 UY25711 A1 UY 25711A1
- Authority
- UY
- Uruguay
- Prior art keywords
- particles
- active agent
- growth inhibitor
- administration
- alveoli
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 8
- 239000002245 particle Substances 0.000 abstract 12
- 239000003966 growth inhibitor Substances 0.000 abstract 5
- 210000004072 lung Anatomy 0.000 abstract 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 abstract 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 229920001605 Dextranomer Polymers 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 229960002086 dextran Drugs 0.000 abstract 1
- 229960002864 dextranomer Drugs 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229940050526 hydroxyethylstarch Drugs 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- -1 maltodextran Polymers 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Partículas para la administración de un agente activo a los alvéolos de un paciente humano, partículas que contienen el agente activo y un inhibidor del crecimiento higroscópico que está incorporado al interior de las partículas y éstas exhiben una caída de la dosis emitida, en condiciones pulmonares simuladas, de no más de aproximadamente 25%. Las particulas en la cuales el inhibidor del crecimiento higrocópico es seleccionado entre el grupo que consiste en fosfolipidos de cadena doble, ciclodextrinas hidroxietilalmidón, dextrano, dextranómero, maltodextrano, hidroxipropilcelulosa, hidroxipropilmetilcelulosa, éter hidroxietilico de etilcelulosa. Particulas para la administración de un agente activo a los alvéolos de un paciente humano, particulas que contienen el agente activo y un inhibidor del crecimiento higroscopico incorporado al interior de las particulas que contienen el agente activo y un inhibidor del crecimiento higroscópico incorporado al interior de las particulas, donde dichas particulas mantienen una distribución de tamaño de particulas del aerosol inferior a 3 micrones de MMAD al ser administradas a los alvéolos. Un método para aumentar la cantidad de un agente activo inhalado deposiado en la profundidad del pulmón, que consiste en: incorporar a dichas particulas de polvo seco con contenido de agente activo para la inhalación, un agente inhibidor del crecimiento higrocópico de manera que, al ser aerosolizadas e inhaladas las particulas, por lo menos el 20% de la dosis nominal se deposite en la profundidad del pulmón.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10016398P | 1998-09-14 | 1998-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25711A1 true UY25711A1 (es) | 1999-11-17 |
Family
ID=22278404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25711A UY25711A1 (es) | 1998-09-14 | 1999-09-14 | Administración de agente activo en polvo seco |
Country Status (44)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| JP4874483B2 (ja) | 1999-06-09 | 2012-02-15 | ロバート イー． シーバース | 超臨界流体補助ネブライゼーション及びバブル乾燥 |
| US6475468B2 (en) * | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| EG24184A (en) | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| CA2465675C (en) | 2001-11-20 | 2008-06-10 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
| US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
| UA83341C2 (uk) | 2002-02-25 | 2008-07-10 | Дифьюжен Фармасьютикалз Ллк | Біополярні солі транс-каротиноїдів та їх використання |
| AU2003232081B2 (en) * | 2002-07-03 | 2009-02-05 | Brandeis University | Central airway administration for systemic delivery of therapeutics |
| CA2511385A1 (en) * | 2002-12-19 | 2004-07-22 | Pharmacia Corporation | Non-hygroscopic formulation comprising a hydroscopic drug |
| DE10338403A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2909080T3 (es) | 2004-04-23 | 2022-05-05 | Cydex Pharmaceuticals Inc | Formulación de DPI que contiene sulfoalquil éter ciclodextrina |
| US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
| BRPI0608844A2 (pt) * | 2005-03-09 | 2010-02-02 | Ono Pharmaceutical Co | partìcula e preparação que contém a partìcula |
| ES2526903T3 (es) | 2005-10-26 | 2015-01-16 | Cydex Pharmaceuticals, Inc. | Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US20080035143A1 (en) * | 2006-08-14 | 2008-02-14 | Sievers Robert E | Human-powered dry powder inhaler and dry powder inhaler compositions |
| KR20090081407A (ko) * | 2006-10-25 | 2009-07-28 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 고결 방지 과립상 제제 |
| EP1925295A1 (de) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stabile Pulverformulierung enthaltend ein Anticholinergikum |
| MX2009010988A (es) | 2007-04-13 | 2010-03-15 | Diffusion Pharmaceuticals Llc | Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica. |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| MX2010004803A (es) | 2007-10-31 | 2010-09-09 | Diffusion Pharmaceuticals Llc | Una nueva clase de composiciones terapeuticas que mejoran la difusion de moleculas pequeñas. |
| US9610343B2 (en) * | 2009-05-20 | 2017-04-04 | Aeras Global Tb Vaccine Foundation | Stable, spray dryed, immunogenic, viral compositions |
| EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
| ES2654945T3 (es) | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
| US9682096B2 (en) | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| WO2015042352A1 (en) * | 2013-09-20 | 2015-03-26 | Virginia Commonwealth University | Delivery of particles using hygroscopic excipients |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| WO2017165667A1 (en) | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
| US20220378727A1 (en) * | 2021-05-14 | 2022-12-01 | The University Of Hong Kong | Dry powder formulations of tamibarotene for pulmonary and intranasal delivery |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155573A (en) * | 1958-05-06 | 1964-11-03 | Benger Lab Ltd | Inhalant composition and method of making same |
| ATE222754T1 (de) * | 1992-06-12 | 2002-09-15 | Teijin Ltd | Ultrafeines pulver zur inhalation und dessen herstellung |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| WO1998031346A1 (en) * | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6086376A (en) * | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
-
1999
- 1999-09-09 MA MA25762A patent/MA25590A1/fr unknown
- 1999-09-13 CA CA002343920A patent/CA2343920A1/en not_active Abandoned
- 1999-09-13 EE EEP200100151A patent/EE200100151A/xx unknown
- 1999-09-13 IL IL14156299A patent/IL141562A0/xx not_active IP Right Cessation
- 1999-09-13 NZ NZ510168A patent/NZ510168A/en unknown
- 1999-09-13 WO PCT/US1999/021109 patent/WO2000015262A1/en not_active Ceased
- 1999-09-13 UA UA2001031707A patent/UA76085C2/uk unknown
- 1999-09-13 TW TW088115876A patent/TWI226248B/zh not_active IP Right Cessation
- 1999-09-13 OA OA1200100063A patent/OA11781A/en unknown
- 1999-09-13 JP JP2000569846A patent/JP2002524535A/ja not_active Withdrawn
- 1999-09-13 HN HN1999000159A patent/HN1999000159A/es unknown
- 1999-09-13 DZ DZ990192A patent/DZ2892A1/xx active
- 1999-09-13 ID IDW20010582A patent/ID28845A/id unknown
- 1999-09-13 EP EP99969035A patent/EP1117442A1/en not_active Withdrawn
- 1999-09-13 AR ARP990104587A patent/AR022090A1/es unknown
- 1999-09-13 CZ CZ2001829A patent/CZ2001829A3/cs unknown
- 1999-09-13 AU AU60397/99A patent/AU753014B2/en not_active Ceased
- 1999-09-13 PE PE1999000925A patent/PE20001061A1/es not_active Application Discontinuation
- 1999-09-13 CN CN99810871A patent/CN1317977A/zh active Pending
- 1999-09-13 YU YU24201A patent/YU24201A/sh unknown
- 1999-09-13 AP APAP/P/2001/002093A patent/AP1374A/en active
- 1999-09-13 GE GEAP19995857A patent/GEP20043257B/en unknown
- 1999-09-13 TR TR2001/01182T patent/TR200101182T2/xx unknown
- 1999-09-13 BR BR9913722-4A patent/BR9913722A/pt not_active IP Right Cessation
- 1999-09-13 SK SK344-2001A patent/SK3442001A3/sk unknown
- 1999-09-13 HU HU0103837A patent/HUP0103837A3/hu unknown
- 1999-09-13 KR KR1020017003208A patent/KR20010075063A/ko not_active Ceased
- 1999-09-13 HR HR20010189A patent/HRP20010189A2/hr not_active Application Discontinuation
- 1999-09-13 HK HK02101738.3A patent/HK1042231A1/zh unknown
- 1999-09-13 MY MYPI99003947A patent/MY129282A/en unknown
- 1999-09-13 ZA ZA200101995A patent/ZA200101995B/en unknown
- 1999-09-13 EA EA200100300A patent/EA003476B1/ru active IP Right Revival
- 1999-09-13 PL PL99346768A patent/PL195574B1/pl not_active IP Right Cessation
- 1999-09-14 PA PA19998481901A patent/PA8481901A1/es unknown
- 1999-09-14 TN TNTNSN99173A patent/TNSN99173A1/fr unknown
- 1999-09-14 GT GT199900156A patent/GT199900156A/es unknown
- 1999-09-14 CO CO99058265A patent/CO5130023A1/es unknown
- 1999-09-14 UY UY25711A patent/UY25711A1/es not_active Application Discontinuation
- 1999-10-31 SA SA99200718A patent/SA99200718B1/ar unknown
-
2001
- 2001-02-21 IL IL141562A patent/IL141562A/en unknown
- 2001-03-05 IS IS5878A patent/IS5878A/is unknown
- 2001-03-13 NO NO20011251A patent/NO20011251L/no not_active Application Discontinuation
- 2001-03-14 LT LT2001021A patent/LT4897B/lt not_active IP Right Cessation
- 2001-03-14 LV LV010041A patent/LV12658B/xx unknown
- 2001-04-10 BG BG105430A patent/BG105430A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25711A1 (es) | Administración de agente activo en polvo seco | |
| AU710821B2 (en) | Fluticasone propionate formulations | |
| US8858917B2 (en) | Methods for limiting spread of pulmonary infections | |
| Conley et al. | Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice | |
| US20070292519A1 (en) | Method of producing a nicotine medicament and a medicament made by the method | |
| Thomson et al. | No demonstrable effect of S-carboxymethylcysteine on clearance of secretions from the human lung. | |
| CZ299348B6 (cs) | Aerosolový prostredek | |
| JP2009529561A (ja) | ニコチンの速やかな放出をもたらす安定なロゼンジ組成物 | |
| KR20090055606A (ko) | 지향성 용도 | |
| PT756868E (pt) | Composicoes em aerossois | |
| UY23356A1 (es) | Preparado para la liberacion retardada de sustancias activas, que son apropiadas como sistema terapeutico o para mejorar el crecimiento y el aprovechamiento de los piensos en rumiantes | |
| AR018891A1 (es) | Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol | |
| US20120042886A1 (en) | Method of producing a nicotine medicament and a medicament made by the method | |
| Moosavi et al. | Early radiation dose-response in lung: an ultrastructural study | |
| US3667478A (en) | Filter cigarette incorporating vitamin a | |
| CA3019748A1 (en) | Ophthalmic composition comprising pvp-i | |
| RU2701514C2 (ru) | Антивирусная фармацевтическая композиция | |
| US9427443B2 (en) | Anaesthetic composition | |
| FI962056A0 (fi) | Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan | |
| Niven et al. | Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein | |
| KR20140001877A (ko) | 흡입 데누포솔에 의한 낭포성 섬유증의 치료 방법 | |
| US20050220720A1 (en) | Formulations limiting spread of pulmonary infections | |
| JP2024128022A (ja) | 微生物感染を消毒、処置および予防するための組成物および方法 | |
| DK168191B1 (da) | Anvendelse af peroxydiphosphater til fremstilling af farmaceutiske tabletter eller farmaceutiske vandige opløsninger | |
| US11903925B2 (en) | Compositions for preventing and treating pulmonary injury due to ionizing radiation or cytotoxic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20081203 |